Dynavax price target raised to $27 from $25 at JMP Securities

JMP Securities analyst Roy Buchanan raised the firm’s price target on Dynavax to $27 from $25 and keeps an Outperform rating on the shares. Dynavax reported another strong quarter for HEPLISAV-B, exceeding consensus estimates and raising FY23 guidance, while management reiterated its expectations for the HepB vaccine market outlook of $800M+ in 2027 and majority market share, the analyst tells investors in a research note.